SCHEMBL5640869

SCHEMBL5640869

COC(=O)N1CCCC[C@H](NC=O)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.39
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MMP1 P03956 8/20 0.32
MMP3 P08254 8/20 0.32
ADH1B P00325 2/20 0.32
ADH1C P00326 2/20 0.32
ADH1A P07327 2/20 0.32
ADH7 P40394 1/20 0.32
ALDH1A1 P00352 2/20 0.31
XIAP P98170 1/20 0.31
ADH4 P08319 1/20 0.31
THRB P10828 1/20 0.31
ATM Q13315 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PDE4B Q07343 3/20 0.30
PDE4A P27815 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638512 0.87 THRB (0.43) NAAAMEN1KMT2AKDM4EALDH1A1
SCHEMBL5637448 0.85 ADH1B (0.33) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL5639328 0.84 HPGD (0.37) MEN1KMT2AADH1BADH1CADH1A
SCHEMBL5637029 0.82 POLB (0.35) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL5637709 0.82 POLB (0.35) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL5638209 0.82 ADH1B (0.33) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL5639312 0.81 FAAH (0.37) NAAAALDH1A1
SCHEMBL5640952 0.81 MEN1 (0.36) MEN1KMT2AADH1BADH1CADH1A
SCHEMBL5637733 0.81 CCR2 (0.35) NAAAADH1BADH1CADH1AADH7
SCHEMBL5638651 0.81 LIPE (0.36) ADH1BADH1CADH1AADH7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 NAAA 3017/4885MEN1 4119/4885KMT2A 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.